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Abstract
Src kinase is an attractive target for drug development based on its established relationship with cancer and possible link to
hypertension. The suitability of traditional Chinese medicine (TCM) compounds as potential drug ligands for further
biological evaluation was investigated using structure-based, ligand-based, and molecular dynamics (MD) analysis.
Isopraeroside IV, 9alpha-hydroxyfraxinellone-9-O-beta-D-glucoside (9HFG) and aurantiamide were the top three TCM
candidates identified from docking. Hydrogen bonds and hydrophobic interactions were the primary forces governing
docking stability. Their stability with Src kinase under a dynamic state was further validated through MD and torsion angle
analysis. Complexes formed by TCM candidates have lower total energy estimates than the control Sacaratinib. Four
quantitative-structural activity relationship (QSAR) in silico verifications consistently suggested that the TCM candidates
have bioactive properties. Docking conformations of 9HFG and aurantiamide in the Src kinase ATP binding site suggest
potential inhibitor-like characteristics, including competitive binding at the ATP binding site (Lys295) and stabilization of the
catalytic cleft integrity. The TCM candidates have significantly lower ligand internal energies and are estimated to form more
stable complexes with Src kinase than Saracatinib. Structure-based and ligand-based analysis support the drug-like
potential of 9HFG and aurantiamide and binding mechanisms reveal the tendency of these two candidates to compete for
the ATP binding site.
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Introduction
Src kinases are nonreceptor tyrosine kinases that are of
physiological importance in cell survival, bone metabolism,
angiogenesis, proliferation, migration, and invasion [1]. Overex-
pression of Src kinase has been linked to various cancers and is
now a well-established proto-oncogene [2–7]. The physiological
pathway involved in hypertension is also associated with Src-
dependent signaling pathways, suggesting a potential link between
hypertension and Src [8–15].
Figure 1 illustrates the components of Src kinase and its
activation mechanism [16,17]. In general terms, the catalytic
activity of Src is co-regulated by SH3 and SH2 domains. Src is
locked in the closed conformation (inactive) when SH2 binds to
the phosphorylated Tyr530, and SH3 binds with prolines on the
linker domain (Figure 1A). When Tyr530 is dephosphorylated, Src
assumes an open conformation, achieving full activity when
Tyr416 within the catalytic domain is autophosphorylated
(Figure 1B). This opening of the Src structure frees the SH2 and
SH3 domains to interact with surface receptors such as focal
adhesion FAK and initiate downstream signaling governing the
aforementioned physiological pathways [1]. In this regard,
inactivation of Src can be achieved through hindering disassembly
of the regulatory SH2 and SH3 Src domains, or by inhibiting ATP
binding to the Src catalytic site [16,18].
Many small molecular Src inhibitors have been identified due to
the involvement of Src in cancer. Comprehensive reviews on such
advancements are detailed elsewhere [16]. Most Src inhibitors
discovered to date are Type I inhibitors that compete with ATP
for binding at the ATP binding pocket [19,20]. Structures of the
three most studied Type I inhibitors Bosutinib, Dasatinib, and
Saracatinib and are shown in Figure 2 along with their respective
status in clinical trials [21–32]. The varying efficacies of these
commercial drugs highlight the need for novel compounds that
can exhibit more consistent inhibition of Src.
The goal of this research is to investigate novel small compounds
from traditional Chinese medicine (TCM) that may be potential Src
kinase ligands. During the past decade, our laboratory has focused
on constructing the most comprehensive TCM database (TCM
Database@Taiwan, url:) (http://tcm.cmu.edu.tw/) [33]. In addi-
tion, we’ve also developed the first cloud-computing webserver
based on TCM Database@Taiwan, url: (http://iscreen.cmu.edu.
tw/) [34] and an integrative website combining TCM and systems
biology (http://iSMART.cmu.edu.tw/) [35]. Utilizing these TCM
computational resources, several novel lead compounds from TCM
with application potential for different diseases have been
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the newly updated TCM Database@Taiwan to screen for novel,
TCM-origin ligands with drug-like properties against Src kinase.
Results and Discussion
Docking
Based on the DockScore, top ranking TCM candidates selected
for further investigation were Isopraeroside IV, 9alpha-hydroxy-
fraxinellone-9-O-beta-D-glucoside (9HFG), and aurantiamide
(Table 1). Isopraeroside IV is a coumarin isolated from the root
of Angelica dahurica [45]. 9HFG originates from the root of
Dictamnus dasycarpus, which has been used as a folk remedy for
inflammation and skin ailments [46]. Aurantuamide is a
composition of Curcuma wenyujin, a dried rhizome used for bleeding
and menstrual disorders in traditional Chinese medicine. Struc-
tural comparisons of the TCM candidates with Saracatinib are
illustrated in Figure 3.
DockScore is the negative sum of the ligand/receptor
interaction and the ligand internal energy calculated by DS. For
clarification purposes, the ligand internal energy consists of a van
der Waals (vdW) term computed using a standard 9-6 (unsoftened)
potential and an optional electrostatic term. Since TCM
candidates and Saracatinib have similar predicted binding
energies, differences in DockScore were primarily affected by the
respective calculated ligand internal energies of each compound
(Table 1). The low DockScore observed for Saracatinib is mainly
due to its high calculated ligand internal energy. The positive
ligand internal energy value is indicative of a highly strained
chemical structure, a phenomenon commonly observed among
synthetic compounds. By contrast, low calculated ligand internal
energies of the TCM compounds suggest energetically stable
structures in which intermolecular atoms are not too close to
exhibit replusion and result in high DockScore values. Based on
DS2.5 calculations, the TCM candidates have higher DockScores
and binding energies comparable to Saracatinib, which may lead
to equal if not better binding to the Src kinase binding site
compared to Saracatinib.
The ADMET properties of the TCM candidates are summa-
rized in Figure 4 and Table 2. All candidates were estimated to be
within the 99% adsorption ellipse (Figure 4) and have good to
moderate adsorption (Table 2). The TCM candidates are more
highly bound to plasma proteins, and less likely to inhibit
cytochrome P4502D6 metabolism.
As our designated binding site overlapped with the Src kinase
ATP binding pocket, it is referred to as the latter for clarification
purposes. Docking poses of the candidates in the ATP binding
pocket are illustrated in Figure 5. The docking model of
Saracatinib indicates p-interactions with Leu273 and Lys295,
and an H-bond with Met341 within the ATP binding pocket
(Figure 5A). Isopraeroside IV formed a total of five H-bonds with
Met341, Ser345, Asp348 (Figure 5B), possibly contributing to the
high estimated binding energy in Table 1. The three hydroxyl
groups on the cyclohexane moiety of 9HFG interacted with
Lys295, Met341, and Asp404, forming a total of five H-bonds
(Figure 5C) in which three were formed with Lys295. Auraniamide
interacted with Leu273, Lys295, Ser345, Asp348, forming two p
interactions at the terminal benzenes with Leu273 and Lys295 and
H-bonds with Ser345 and Asp 348 (Figure 5D).
Ligplot diagrams illustrating hydrophobic and H-bond interac-
tions are shown in Figure 6. In general, the higher ability of ligands
to form hydrophobic interactions with hydrophobic amino acids of
the binding site, the higher the binding affinity. As shown in
Figure 6, TCM candidates are surrounded by hydrophobic amino
acids, therefore are harder to remove from the ATP binding
pocket under physiologically dynamic conditions. Less hydropho-
bic interactions were formed by Saracatinib. Minor variations in
H-bond formation were observed in LigPlot diagrams compared
to 3D-docking poses generated by DS 2.5 (Figure 5). Additional H-
bonds were formed with Tyr340 and Glu399 by Isopraeroside IV
(Figure 6B). 9HFG formed two additional H-bonds at Ala390 and
Asn391 (Figure 6C). In auraniamide (Figure 6D), the H-bonds at
Leu273 and Lys295 were replaced by hydrophobic interactions.
These differences may be due to the DS cutoff distance of 2.5 A ˚ or
to the HBPLUS program used to calculate H-bonds in LigPlot.
The number of H-bonds and hydrophobic interactions deter-
mined through LigPlot is summarized in Table 3. These
simulation results suggest that TCM candidates have a higher
number of stabilizing interactions than Saracatinib.
Key amino acids and important structural moieties can be
summarized based on the docking simulation results. Leu273 is
important for H-bonds and p-interactions, and ligands form
interactions with its nonpolar, aliphatic alkyl group. Saracatinib,
9HFG, and auraniamide interact with Src kinase through Lys295.
The importance of Lys295 is reinforced by the three H-bonds and
two p-interactions formed by the aforementioned ligands. Other
amino acids serving as anchor points in the Src kinase ATP
binding pocket include Met341, Ser345, Asp348, and Asp390.
The chemical structures of the candidates facilitate hydrophobic
interactions with surrounding amino acids, and enable higher
ligand-protein affinity and complex stability.
Bioactivity Prediction by SVM and MLR
The 75 descriptors relevant to the training set were determined
and GFA further employed to determinethe top tendescriptors that
could most accurately describe the training set. The descriptors thus
determined were: C_Count (the amount of carbon atoms within the
ligand), ES_Sum_sCH3 (sum of the electrotopological state (E-state)
values for carbons with single bonds), E_ADJ_equ (molecule
differentiation based on edge adjacency), CHI_2 (number of pairs
of bonds within a molecule), CHI_3_P (number of phosphate
molecules with three bonds), Kappa_2 (shape index of order 2
describing topological descriptors), Kappa_3 (shape index of order 3
describing topological descriptors), Jurs_FNSA_1 (sum of negative
Figure 1. Components of Src and its activation mechanisms. (A)
SH2 binds to the phosphorylated Tyr530 and SH3 binds with prolines
on the linker domain, effectively locking the Src in an inactive closed
conformation. (B) Src is activated when Tyr530 is dephosphorylated and
Tyr416 within the catalytic domain is autophosphorylated.
doi:10.1371/journal.pone.0033728.g001
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area), Jurs_PNSA_1 (sum of solvent-accessible surface areas of all
negatively charged atoms), Shadow_nu (characterizes molecule shape
using ratio of largest to smallest dimension).
Using these descriptors, the MLR model generated was:
pIC50~ 13:037z0:67442 C Count 0:22096 ES Sum sCH3 
0:18787   E ADJ equz6:4515   CHI 2z
1:345   CHI 3 Pz1:5976   Kappa 2 4:0379   Kappa 3
 47:403   Jurs FNSA1z0:065128   Jurs PNSA 1 
0:50161   Shadow nu
As shown in Figure 7, the square correlation coefficients for the
MLR and SVM models were 0.837 and 0.7922, respectively,
indicating reliable models. Predicted bioactivities (pIC50) of the
TCM candidates by the generated MLR and SVM models are
listed in Table 2. Both models predicted higher pIC50 values for
Isopraeroside IV and 9HGF than aurantiamide. The predicted
bioactivities for Saracatinib was 4.9410 using MLR and 7.3036
using SVM. These predicted results, when compared to the in vitro
inhibition concentration of Saracatinib (pIC50=8.57) [47],
indicate that values predicted by the SVM model may be closer
to actual inhibition concentrations observed in vitro. The higher
accuracy of the SVM model is expected as its predictions are
generated on a non-linear model.
Figure 2. Scaffolds of Bosutinib, Dasatinib, amd Saracatinib, and their respective status in clinical trials.
doi:10.1371/journal.pone.0033728.g002
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Table 4 summarizes the PLS results of CoMFA and CoMSIA
models. Steric fields are the dominant factor in CoMFA. Under an
optimal number of components (ONC) of 6, cross-validated
correlation coefficient (q
2) and non-cross-validated correlation
coefficient (r
2) of 0.430 and 0.920 indicate a reliable model.
Multiple CoMSIA models were generated using different factor
combinations (Table 4). Models SHD and SEHD were the best
overall models with high q
2 (q
2.0.4), high r
2, low SEE, and large
F values. However, addition of an electrostatic variable in model
SEHD did not significantly increase model correlation or strength
(F-value), thus model SHD was selected as the optimum CoMSIA
model. Reliability of the selected CoMFA and CoMSIA models
are validated by the q
2 and r
2 values (Table 4).
The observed, predicted and calculated residual pIC50 values of
the training and test set compounds by CoMFA and CoMSIA are
summarized in Table S1. Differences between observed and
predicted pIC50 ranged between 20.667 and 1.066. Residuals
using the CoMSIA model ranged from 20.5 to 0.821, indicating
high accuracy of the predictions from our generated model with
actual biologically verified values. All ratio values calculated
through CoMSIA were within 160.1 indicating high accuracy.
The correlation coefficient between the observed and predicted
pIC50 using the CoMFA model was 0.8448 (Figure 8A). With the
CoMSIA model, the correlation coefficient was 0.9014 (Figure 8B).
Both models are highly reliable.
Superimposing CoMFA and CoMSIA contour maps on
Saracatinib and the TCM candidates provide insights into the
predicted bioactivity of the compounds. Saracatinib (Figure 9A),
Isopraeroside IV (Figure 9B), and 9HFG (Figure 9C) contoured
well to the CoMFA model. No bulk structures were located in the
steric disfavoring (yellow) region. In addition, bulky ring moieties
in Saracatinib and 9HFG were located in the steric favoring
(green) region. By comparison, a benzene ring of aurantiamide
was located within the steric disfavoring region, suggesting a lower
biological activity due to its deviation from the CoMFA contour
map (Figure 9D). These results agree with the MLR and SVM
results in which aurantiamide had the lowest predicted bioactivity
Table 1. DockScore and related attributes of Sacracatinib and
top three TCM candidates calculated by Discovery Studio 2.5
(D.S. 2.5).
Name
Ligand Internal
Energy Binding Energy Dock Score
Isopraeroside IV 242.52 263.39 97.28
9HFG 235.33 260.24 93.12
Aurantiamide 237.24 257.12 83.02
Saracatinib* 34.20 260.81 27.09
Candidates ranked by Dock Score.
*Control.
9HFG: 9alpha-hydroxyfraxinellone-9-O-beta-D-glucoside.
doi:10.1371/journal.pone.0033728.t001
Figure 3. Structural scaffolds of TCM candidates and Saraca-
tinib. (A) Saracatinib, (B) Isopraeroside IV, (C) 9HFG, and (D)
aurantiamide.
doi:10.1371/journal.pone.0033728.g003
Figure 4. ADMET adsorption model of Saracatinib and the TCM candidates generated by DS 2.5.
doi:10.1371/journal.pone.0033728.g004
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Saracatinib forms H-bonds with Met341 which is located near the
region favoring hydrogen bond donors (purple) and hydrophobic
interactions (cyan) (Figure 10A). Isopraeroside IV was a smaller
compound and its interactions with Src did not fall within the
disfavoring regions of the CoMSIA map (Figure 10B). A similar
contour was observed in 9HFG (Figure 10C). In aurantiamide, the
benzene moieties were in proximity to the steric disfavoring
regions, suggesting a lower bioactivity of the ligand (Figure 10D).
Results of the ligand-based studies are consistent, and suggest high
bioactivity for Saracatinib, moderate to high bioactivity for
Isopraeroside and 9HFG, and moderate to low bioactivity for
aurantiamide.
Molecular Dynamics Simulation
More realistic interactions of the candidates with Src kinase in a
biological system were simulated through MD. Interaction
differences at key residues for each tested compound during
docking and MD are summarized in Table 5. H-bond formation
and occupancies during and the H-bond distance profiles are
presented in Table 6 and Figure 11, respectively. The primary
binding residue for Saracatinib was Lys295 where stable p-
interactions and a high occupancy H-bond were formed
(Figure 11A). The H-bond observed at Met341 during docking
was substituted by an H-bond with Thr338 throughout MD. The
p interaction with Leu273 during docking was not observed during
MD. As illustrated in Figure 12A, the head-on direction of the H
atom and the near perpendicular spatial arrangements facilitate
the formation of p-sigma interaction between Leu273 and
Saracatinib. During MD, angle increase due to ligand and
Leu273 fluctuations disrupted the formation of p-sigma interac-
tions (Figure 12A).
Isopraeroside IV formed stable H-bonds with Met341, Lys343,
and Ser345 (Table 6). H-bonds formed with Tyr340 (Figure 11B)
and Asp348 (Figure 11C) were not stable and could not contribute
to stability of Isopraeroside when in complex with Src kinase.
Sharp decreases in H-bond distances observed for Lys343 and
Ser345 (Figure 11B–C) are likely due to rotations of the residues
which bring the ligand into closer proximity for H-bond formation
(Figure 13A).
The highest number of H-bonds was formed by 9HFG with
Lys295 and Asp404 (Table 5–6) Rhythmic fluctuations of H-bond
distances with the key binding residue Lys295 (Figure 11D–F) are
likely due to rotations of the amine group on Lys295 (Figure 13B).
9HFG also formed two H-bonds with Asp404, but the H-bond
with Ala390 during docking was lost (Figure 11G).
Aurantiamide was primarily bound to the ATP binding pocket
through the p interaction at Lys295 and H-bonds with Ser345 and
Asp348 (Table 5). Increased distance fluctuations in Ser345
(Figure 11H) could be due to the rotation of benzene moieties
(Figure 13C). Similar to Saracatinib, the loss of the p interaction at
Leu273 involved torsion of the benzene moiety (Figure 12B).
Benzene ring torsion during MD reduced angles between the H
Table 2. Adsorption, distribution, metabolism, toxicity properties and predicted pIC50 of Saracatinib and the top three TCM
compounds.
Name
ADMET Adsorption
Level
1
PPB
Level
2
CYP2D6
Probability
3 Hepatoxicity
4 Bioactivity Prediction (pIC50)
SVM MLR
Isopraeroside IV 1 2 0.356 0 6.0277 7.7282
9HFG 1 2 0.297 0 6.8590 7.5342
Aurantiamide 0 2 0.475 0 4.6490 4.4080
Saracatinib* 0 0 0.297 0 7.3036 4.9410
*Control.
1ADMET Adsorption levels: 0=Good; 1=Moderate; 2=Low; 3=Very low.
2Plasma Protein Binding: 0=Binding ,90% ;1=Binding .90%; 2=Binding .95%.
3Inhibition probability of Cytochrome P450 2D6 enzyme.
4Hepatoxicity: 0=Nontoxic; 1=Toxic.
doi:10.1371/journal.pone.0033728.t002
Figure 5. Docking poses of different ligands in Src kinase ATP
binding pocket. Shown are snapshots of (A) Saracatinib,(B) Isopraero-
side IV, (C) 9HFG, and (D) aurantiamide during docking simulation with
Src kinase. Purple and blue surfaces are added to denote the small lobe
(267–337) and large lobe (340–520) of Src kinase, respectively.
Hydrogen bonds are shown as dotted green lines and pi-interactions
are shown in orange. (A) Pi-interactions with Lys273 and Lys295 are
critical for Saracatinib. (B) Isopraeroside IV docks to the outer region of
the ATP binding pocket via H-bonds at Ser345 and Asp348. (C) 9HFG
structure enables docking in the inner regions of the ATP binding
pocket, forming H-bonds with Lys295 and Asp404. (D) Similar to
Saracatinib, aurantiamide forms pi-interactions with Lys295, in addition
to H-bonds with Ser345 and Asp348.
doi:10.1371/journal.pone.0033728.g005
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aurantiamide. Hydrophobic interactions are represented by red spokes radiating towards the ligand atoms they contact. Ligands are represented in
purple. C, N, O, and Cl atoms are represented in black, blue, red, and green, respectively. Pink backgrounds highlight amino acids of the small lobe
(267–337), and blue background highlight those belonging to the large lobe (340–520). Hydrophobic interactions shown in this illustration are
calculated through the Ligplot algorithm.
doi:10.1371/journal.pone.0033728.g006
Table 3. Ligand-protein interactions determined through LigPlot.
Amino acid in Src kinase
Hydrophobic
interactions
1 Ligand
Saracatinib Isopraeroside IV 9HFG Aurantiamide
Leu273/Leu393 + A/A A/A A/A A/A
Gly274/Gly344 + -/A A/A -/A A/A
Val281 + -A A A
Ala293/Ala390 + - A/- H1 -
Lys295 + -- H 2 A
Tyr340 + AH 1 - -
Met341 2 H1 H1 - -
Ser345 2 -H 2 A H 1
Asp348/Asp404 2 - H2/- -/H1 H1/A
Asn391 2 -- H 1 -
Glu399 2 -H 1 H 1 -
1Amino acid residues where hydrophobic interactions are observed are denoted by the ‘‘+’’ symbol.
A: hydrophobic interaction.
H1: form one hydrogen bond between ligand and amino acid.
H2: form two hydrogen bond between ligand and amino acid.
doi:10.1371/journal.pone.0033728.t003
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1.
Cross validation Non-cross validation Fraction
ONC q
2cv r
2 SEE F S E H D A
CoMFA 6 0.430 0.920 0.291 68.862 1 0 - - -
CoMSIA
S 6 0.567 0.879 0.357 43.751 1 - - - -
H 6 0.449 0.922 0.287 70.832 - - 1 - -
SA 5 0.370 0.821 0.428 34.018 0.587 - - - 0.413
SE 5 0.468 0.845 0.399 40.426 1 0 - - -
SH 6 0.486 0.935 0.262 86.523 0.367 - 0.633 - -
HD 6 0.499 0.929 0.273 78.719 - - 0.695 0.305 -
SEH 5 0.527 0.914 0.298 78.403 0.368 0 0.632 - -
SHD* 6 0.519 0.944 0.244 100.517 0.260 - 0.468 0.272 -
SHA 6 0.439 0.936 0.260 87.726 0.293 - 0.492 - 0.215
EHD 6 0.531 0.929 0.273 78.719 - 0 0.695 - 0.305
HDA 5 0.446 0.928 0.275 77.512 - - 0.550 0.253 0.197
SEHD 6 0.539 0.944 0.244 100.517 0.261 0 0.468 0.272 -
SEHA 5 0.506 0.920 0.286 85.421 0.287 0 0.485 - 0.228
SHDA 6 0.467 0.946 0.238 105.771 0.222 - 0.400 0.219 0.158
EHDA 6 0.464 0.928 0.275 77.512 - 0 0.550 0.253 0.197
SEHDA 6 0.452 0.946 0.238 105.771 0.222 0 0.400 0.219 0.158
1: Structures and inhibitory activities adapted from [54].
ONC: Optimal number of components.
S: Steric.
SEE: Standard error of estimate.
E: Electrostatic.
F: F-test value.
H: Hydrophobic.
PLS: partial least squares.
D: Donor.
*: Optimum prediction model.
A: Acceptor.
doi:10.1371/journal.pone.0033728.t004
Figure 7. Correlation between observed and predicted activities of 53 Src inhibitors using different prediction models. (A) MLR and
(B) SVM. Correlation coefficients (R
2) calculated from the training set were 0.837 and 0.7922 for MLR and SVM models respectively.
doi:10.1371/journal.pone.0033728.g007
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making the formation of p-interactions unlikely (Figure 12B). In
general, MD results were in agreement with docking (Table 5).
Torsion angles also provide molecular insights into ligand
stability (Figure 14). Torsion angle fluctuations critical to the
stability of Saracatinib were not observed (Figure 14A). Torsion
angles recorded for Isopraeroside IV were relatively stable with the
exception of c and d (Figure 14B). Notable torsion angle changes
at c and d, may account for the decrease in H-bond distances
observed for Tyr340 (6.34 ns) (Figure 11B). Subsequent increase in
bond distance and resulting loss of the Tyr340 H-bond could be
due to sharp angle changes of d from 17.44 ns to the end of MD
simulation. Torsion angles for 9HFG provide supporting evidence
for the cause of H-bond fluctuations in Figure 11D–G. Since the
stable torsion angles at c and e (Figure 14C) imply a relatively
stable ligand, fluctuations in bond distance (Figure 11D–F) should
be due to changes in Lys295. Further evidence is given by torsion
angle changes at f.A sf is associated with the binding of O9 with
Lys295 and H39 with Asp404, should ligand stability be the cause
of fluctuation, bond distances at both locations should be equally
affected. However, H39 forms stable H-bond with Asp404, but O9
Figure 8. Correlation between observed and predicted activities of 53 Src inhibitors using different 3D-QSAR models. (A) CoMFA and
(B) CoMSIA. Correlation coefficients (R
2) calculated from the training set were 0.8448 and 0.9014 for CoMFA and CoMSIA models respectively.
doi:10.1371/journal.pone.0033728.g008
Figure 9. Spatial contour of test ligands to generated CoMFA
maps. Map areas favoring and disfavoring steric fields are represented
respectively in green and yellow. Saracatinib (A), Isopraeroside IV (B),
and 9HGF (C) contoured well to the bioactivity map. A benzene ring of
aurantiamide was located within the steric disfavoring region (D),
suggesting lower bioactivity than it other tested ligands.
doi:10.1371/journal.pone.0033728.g009
Figure 10. Spatial contour of test ligands to generated CoMSIA
maps. Color blocks represent favor/disfavor steric field (green/yellow),
favor/disfavor hydrophobic interaction (cyan/white), favor/disfavor
hydrogen donor (purple/magenta). Saracatinib (A) forms H-bonds with
Met341 which is located near the region favoring hydrogen bond
donors and hydrophobic interactions. The compact structures of
Isopraeroside IV (B) and 9HGF (C) allowed interactions with Src kinase
without defying regions disfavoring interactions. The benzene moieties
of aurantiamide (D) were in proximity to the steric disfavoring region,
suggesting lower bioactivity.
doi:10.1371/journal.pone.0033728.g010
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Ligand Interaction Location/Type/Frequency*
Leu273 Lys295 Thr338 Tyr340 Met341 Lys343 Ser345 Asp348 Ala390 Asp404
Saracatinib-docking pp H
Saracatinib-MD pHH H
Isopraeroside IV-docking H HH HH
Isopraeroside IV-MD H H HHH
9HFG HHH HH
9HFG-MD HHHHHH HH
Aurantiamide pp HH
Aurantiamide-MD p HH
*: each letter denotes one interaction.
p: pi-interaction.
H: H-bond.
doi:10.1371/journal.pone.0033728.t005
Table 6. H-bond distance and occupancies
1 of different ligands during MD.
Ligand H-bond Ligand Atom Amino acid Distance (A ˚)
H-bond
occupancy
Max. Average Min.
Saracatinib 1 O24 LYS295:HN 3.865 2.492 1.863 59.8%
2 O24 THR338:HG1 3.875 3.198 2.296 0.1%
3 Cl31 ASP404:HN 5.164 4.193 2.480 0.15%
Isopraeroside IV 1 H50 TYR340:OH 6.354 4.565 1.773 7.75%
2 O15 MET341:HN 4.145 2.655 1.714 39.45%
3 H53 LYS343:O 5.479 2.331 1.746 49.25%
4 H51 SER345:OG 3.933 2.601 1.896 70.55%
5 O27 SER345:HG 4.195 2.894 2.165 7.85%
6 O27 SER345:HN 4.094 2.976 1.929 6.7%
7 H51 ASP348:OD2 5.625 4.741 2.193 15.3%
9HFG 1 O9 LYS295:HZ1 3.92 2.358 1.565 60.2%
2 O10 LYS295:HZ1 4.099 2.773 1.61 40.6%
3 O8 LYS295:HZ2 5.772 4.166 2.451 0.05%
4 O9 LYS295:HZ2 3.31 2.327 1.601 63.95%
5 O10 LYS295:HZ2 3.741 2.350 1.592 71.15%
6 O9 LYS295:HZ3 4.354 2.627 1.633 42.85%
7 O10 LYS295:HZ3 4.102 2.637 1.562 57.55%
8 H41 ALA390:O 5.284 3.869 2.186 0.05%
9 H39 ASP404:OD1 4.427 3.246 1.784 14.35%
10 H39 ASP404:OD2 4.427 3.246 1.784 99.4%
Aurantiamide 1 H40 SER345:OG 3.764 2.431 1.743 61.5%
2 H44 ASP348:OD1 3.896 3.182 2.151 0.9%
1: Occupancy calculated based on the default cut-off distance of 2.5 A ˚.
doi:10.1371/journal.pone.0033728.t006
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primary reason for the lack of stable binding with Lys295 is due to
the instability of the amino acid itself. Among the torsion angles
recorded for aurantiamide (Figure 14D), only a, d, and l are
relatively unstable with angle fluctuations greater than 50 degrees.
Stable H-bonds are formed as a result of the stability of the ligand.
Figure 15 summarizes the RMSD and total energy trajectories
of the ligands during MD. All compounds, with the exception of
9HFG from 20–24 ns, had relatively stable ligand RMSDs. Whole
molecule RMSDs and total energies reached equilibration after
16 ns. Among the four test compounds, Saracatinib had the
highest complex RMSD and total energy. The TCM candidates
exhibited similar complex RMSDs, but aurantuamide had
higher total energy than Isopraeroside IV and 9HFG after
stabilization. The higher energy and complex RMSD of
Saracatinib may be associated with its high internal ligand
energy (Table 1). Once bound, the internal energy is transferred
to the complex, causing more fluctuations and higher energy
levels. Isopraeroside IV and 9HFG are smaller structures
compared to Saracatinib. The lower energy profiles and complex
RMSD may be attributed to the compact structures and
formation of multiple H-bonds. Flexible moieties in Isopraero-
side IV are anchored to the ATP binding pocket through H-
bonds, limiting the fluctuations of the complex and increasing
stability. By contrast, H-bonds formed by 9HFG stabilizes the
phenyl moiety, but the remaining structure is unbound and can
freely rotate. This could be the reason for high ligand RMSDs
observed for 9HFG (Figure 15B). Aurantuamide is a larger
compound that shares similarities with Saracatinib. As previously
discussed, aurantuamide interacts with Src kinase ATP binding
pocket through a p interaction with Lys295 and an H-bond at
Ser345, leaving two benzene moieties free for rotation. The
larger ligand RMSD and higher total energy is likely due to these
rotations. In summary, all four test compounds formed stable
complexes at the ATP binding pocket for the duration of MD.
TCM candidates exhibited higher stability than Saracatinib,
indicating advantages as substitutes for the commercial drug.
Assessment of TCM candidate mode of action
Despite promising drug-like characteristics, one must consider
binding mechanisms of the ligand compounds to objectively
speculate their effect on Src kinase. As described previously, most
Src inhibitors, including Saracatinib, compete with ATP for
binding to Lys295 (Type I inhibitors). Src kinase is activated when
interactions between SH2 and SH3 are broken, and when Tyr416
becomes phosphorylated [18] (Figure 1). Among our TCM
candidates, 9HFG and aurantiamide show Src Type I inhibitor-
like docking characteristics. Aurantiamide interacts primarily with
Figure 11. Hydrogen bond distance profiles between Src kinase and TCM candidates during 20 ns MD simulation. Distances (A ˚) shown
are profiles of amino acids implicated as binding residues during docking with (A) Saracatinib, (B,C) Isopraeroside IV, (D–G) 9HFG, and (H) aurantiamide.
doi:10.1371/journal.pone.0033728.g011
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competitive binding against ATP for Lys295 (Figure 16A).
However, its lower total energy (Figure 15) implies a more stable
protein-ligand complex than Saracatinib. Intriguingly, 9HFG is a
potential candidate that mimics the natural autoinhibitory
mechanisms in Src kinases. Not only does 9HFG bind strongly
to Lys295, but it simultaneously binds to Asp404 as well
(Figure 16A). This is an important feature as it mimics the
bridging function of Mg
2+ between these two amino acids in native
Src kinases and stabilizes the structural integrity of the catalytic
cleft (Figure 16B) [18]. The dual function of 9HFG as a binding
site competitor and stabilizer of the catalytic cleft suggests good
potential for Src kinase inhibition. On the contrary, Isopraeroside
IV may not affect Src kinase activity despite its good binding
affinity and predicted bioactivities. Isopraeroside IV binds to
regions located deeper within the catalytic cleft than Lys295
(Table 3, Table 5) and does not interact directly with Lys295.
Though Isopraeroside IV may limit the ability of ATP to bind to
Lys295 through steric hindrance, there is no evidence from our
structure-based analysis to support such a claim.
Conclusion
The potential of Isopraeroside IV, 9HFG, and aurantiamide as
potential leads for Src-kinase was assessed through structure- and
ligand-based in silico approaches. Docking and MD suggest that
Isopraeroside IV, 9HFG, and aurantiamide have higher and more
stable binding affinities with Src kinase than Saracatinib.
Assessment of biological activity through ligand structures further
implied that the TCM candidates were biologically active
compounds. Considering the interaction between the TCM
candidates and the Src ATP binding region, 9HFG, and
aurantiamide may exert inhibition against Src kinase by
competitive binding against ATP. Our results may be applicable
to drug development in different ways. TCM compounds 9HFG
and aurantiamide may be directly used as candidate lead
compounds in biological studies based on their high stability and
predicted bioactivities. In addition, structural insights such as key
amino acids and important moieties which form stable interactions
can be utilized for de novo synthesis of more stable compounds that
interact with Src kinase.
Materials and Methods
Docking
The protein structure of human Src kinase (PDB: 2H8H) was
obtained from Protein Data Bank [47]. The binding site used in
this study was based on the space occupied by Saracatinib within
2H8H. The binding site was located within the cleft separating the
carboxyl-terminal lobe (residues 345–523) and the amino-terminal
lobe (residues 270–340), and surrounded by residues Lys295,
Trp340, Met341, Lys343, Gly344, Ser345, Leu373, Leu393, and
Asp404. Over 20,000 ligands from TCM Database@Taiwan were
used for docking in the Src kinase binding site. All ligands were
pre-treated with CHARMm [48] to attach missing H-atoms.
Saracatinib was used as the control. TCM ligands were docked
into the binding site using the LigandFit program [49] within
Discovery Studio 2.5 and DockScore selected as the primary
scoring function for assessing binding affinities. TCM ligands were
further screened with Lipinski’s Rule of Five [50,51] and
absorption, distribution, metabolism, excretion and toxicity
(ADMET) [52] in DS 2.5 to rule out potentially toxic derivatives.
Figure 12. Molecular changes contributing to the disappear-
ance of pi interactions in Saracatinib and aurantiamide during
MD. Loss of pi-interaction with Leu273 in both ligands was due to
torsion of the benzene ring within the ligand structures.
doi:10.1371/journal.pone.0033728.g012
Figure 13. Molecular changes contributing to protein-ligand
complex stability during MD. (A) Lys343 and Ser345 amine group
rotations bring Isopraeroside IV into proximity for H-bond formation. (B)
The rhythmic fluctuations observed in 9HFG can be attributed to the
rotations of the NH3 group on Lys295. (C) Rotation of the benzene
moieties led to increased distance fluctuations in Ser345 during MD.
doi:10.1371/journal.pone.0033728.g013
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the ligand and protein were analyzed using LigPlot v.2.2.25 [53].
The 3D protein-ligand complexes generated during docking were
flattened to 2D diagrams through the ligplot algorithm.
Bioactivity Prediction by Support Vector Machine (SVM)
and Multiple Linear Regression (MLR)
DS 2.5 was used to calculate individual molecular property
descriptors of 53 Src inhibitors with known pIC50 values [54].
Representative descriptors for the inhibitors were determined from
a pool of 552 descriptors through genetic function approximation
(GFA) [55,56]. A QSAR modelswere calculated by GFA and ranked
by square correlation coefficient (R
2) corresponding to the fitness of
each model. Descriptors from the model with the highest R
2 were
used to construct MLR and SVM models for predicting the
bioactivity of TCM candidates. The linear MLR model [57] was
constructed with the representative descriptors using MATLAB [58].
In addition to the linear MLR model, a non-linear QSAR
model utilizing support vector machine (SVM) [59,60] for the
regression of continuous bioactivity data (pIC50), also termed
support vector regression (SVR), was also constructed. SVR uses
the Kernel function to map the input data set into a high-
dimensional feature space in order to find the hyperplane that best
predicts data distribution. The SVR formulation is
min
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The parameters (x1, y1), …, (xl, yl) represent data within a given
training set and can also be expressed as f(x)=,w,x.+b,
w[Rd,b[R. The parameter w is calculated by performing e-
Figure 14. Torsion angles of test candidates during MD simulation. Torsion angle measured is designated by a lower case alphabet which
corresponds to the radar chart with the same alphabet. Red numbers indicate the locations where H-bonds are formed. (numbering corresponds to
those in Table 5). Blue lines indicate the torsion angles recorded; the red and gray lines indicate the angle during docking and at time 0 of MD,
respectively.
doi:10.1371/journal.pone.0033728.g014
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parameters C,e, the kernel function and kernel parameters. To
further optimize this to nonlinear functions, Lagrange multipliers
and kernel k(x,x9)=Sw(x),w(x0)T are used. The nonlinear functions
and predictions are determined by:
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The SVM model was constructed by applying the LibSVM [61]
within the gridregression.py program to determine key parameters
C cost, epsilon and gamma.
Bioactivity Prediction by 3D Quantitative Structure-
Activity Relationship (QSAR) Analysis
The 53 Src kinase inhibitors [54] used in this study were
randomly divided into a training set of 43 compounds and a test
set of 10 compounds. Alignment of the training set molecules was
performed using atom-fit module of SYBYL-X 1.1 [62] Compar-
ative force field analysis (CoMFA) and comparative similarity
indices analysis (CoMSIA) models were constructed for 3D-
QSAR. The steric and electrostatic field descriptors in CoMFA
were calculated using Lennard-Jones potential and Coulombic
potential, respectively. For CoMSIA models, the steric, electro-
static, hydrophobic and hydrogen bond donor and acceptors were
calculated through Gaussian functions. Partial least squares (PLS)
regression was utilized to analyze the 3D-QSAR models with
descriptor used as an independent variable. Structural contour to
the generated CoMFA and CoMSIA models were used to predict
bioactivity of TCM candidates.
Molecular Dynamics (MD) Simulation
Src kinase complexes of the TCM candidates were subjected to
molecular dynamics (MD) simulation under the force field of
CHARMm [48] using DS 2.5. The energy of each complex was
minimized using 500 steps of Steepest Descent and 500 steps of
Conjugate Gradient method. The system was heated without
constraint from 50 K to 310 K in 50 ps, and equilibrated for
200 ps. The final production was conducted for 40 ns in NVT
ensemble with snapshots saved at 2.5 ps intervals. The time step
was set to 2 fs. Hydrogen bond frequencies, energy trajectories,
and hydrogen bond distances were calculated via DS 2.5 Analyze
Trajectory module to analyze molecular interactions within the
protein-ligand system.
Supporting Information
Table S1 Predicted and observed activity (pIC50) of 53 known
Src kinase inhibitors
1 using generated CoMFA and CoMSIA
models.
(DOC)
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Figure 15. Measured trajectories during MD. (A) Complex, (B)
ligand, and (C) total energy during MD. Saracatinib had the highest
complex RMSD and total energy. The lower complex RMSDs and total
energy of Isopraeroside IV and 9HFG may be attributed to their
compact structure and multiple H-bond formations. The higher RMSD
and total energy observed in auranruamide is possibly the result of the
rotating benzene moieties.
doi:10.1371/journal.pone.0033728.g015
Figure 16. Mechanisms underlying Src kinase inhibition and
activation. (A) Based on the molecular interactions observed through
MD, TCM candidates 9HFG and aurantiamide (A; violet diamond) may
inhibit Src kinase activation through different pathways. Aurantiamide
binds directly to Lys295, competing with ATP for the binding site. 9HGF
also binds to Lys295, but has additional binding with Asp404, which
acts similarly to Mg
2+ found in native Src kinase. (B) The bridging
function of Mg
2+ between Lys295 and Asp404 in native Src kinase.
doi:10.1371/journal.pone.0033728.g016
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